Financial Regulation

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.

CrowdStrike and Schwarz Digits partner to deliver AI-native security on a sovereign EU cloud, answering Europe's call for data control amid new regulations.

Amidst industry consolidation, CPAmerica's expansion highlights why independent CPA firms are leveraging associations to gain a competitive edge and global reach.

Backed by Shift4 and Castle Island, Cyclops aims to simplify stablecoin adoption for payment firms with a new, all-in-one platform.

A new growth medium aims to standardize stem cell production, addressing key regulatory and scalability challenges in the booming regenerative medicine market.

A new poll reveals overwhelming public opposition to a federal plan to stockpile glyphosate, fueled by billions in lawsuits and a retracted safety study.

Pennsylvanians lost over $285 million to scams in one year. AARP is now urging residents to break the silence and report fraud to protect others.

With its Q platform, PMSI is tackling decades of inefficiency, promising to restore trust and transparency to the complex world of mortgage servicing.

A new alliance aims to fight fraud and empower users with a single, secure digital ID for an increasingly complex physical and digital world.

Amid a strategic overhaul, Hepion Pharmaceuticals is licensing a novel RNA-based liquid biopsy, aiming to transform early liver cancer detection.

The new M² card aims to redefine crypto spending with self-custody, user-approved transactions, and a deep integration with decentralized digital identity.

A new report reveals 67% of asset servicing errors stem from bad data. With volumes soaring, firms face a choice: comply with ISO 20022 or transform.

Peli BioThermal and Polar Group partner to upgrade Brazil's pharma logistics, tackling a booming market and ensuring safer delivery of advanced medicines.

EcoVadis awards highlight a major shift: sustainability is no longer about compliance, but a core driver of performance, resilience, and long-term value.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

A $1M deal offers a sliver of recovery for victims of the $71M William Jordan Ponzi scheme, putting custodian Kingdom Trust's alleged role in focus.

Total Joint Orthopedics surpasses 50,000 implants, signaling a major shift as surgeries move from hospitals to efficient, cost-effective surgery centers.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.